Dr. Na Zhang 张娜
Chief Physician
Department of Radiation Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical and basic research in radiotherapy for breast and head and neck cancers. Treatment of lung, esophageal, rectal, breast, nasopharyngeal cancers, and malignant lymphoma.
Dr. Zhang holds a medical doctorate from China Medical University and serves as a master’s supervisor. As Director of the Fifth Radiotherapy Department at Liaoning Cancer Hospital, Dr. Zhang studied breast and head and neck radiotherapy in Europe and North America on government scholarships. Research focuses on precision radiotherapy and multidisciplinary clinical studies. Dr. Zhang has led multiple provincial and national projects and published over 20 papers.
Professional roles
- Member, Radiation Oncology Branch, Liaoning Medical Association
- Member, Radiotherapy Professional Committee, Liaoning Anti-Cancer Association
- Member, Tumor Radiotherapy Professional Committee, Wu Jieping Medical Foundation
- Editorial Board Member, Annals of Palliative Medicine
Name order: in Chinese the family name comes first (Zhang Na). Papers usually list the name as Na Zhang or Zhang N.
Selected publications
29 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): The tumor microenvironment as a key regulator of radiotherapy response. PubMed 41890753
- Clin Exp Metastasis, 2025 (senior author): Laminin α5: a key factor in tumor metastasis. PubMed 40214832
- Sci Rep, 2024 (senior author): Implication of CCNG1 in radiosensitivity via the Wnt/β-catenin pathway in esophageal squamous cells. PubMed 39511268
- Front Pharmacol, 2023 (senior author): The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms. PubMed 37007040
- J Oncol, 2022 (senior author): A New Model for Predicting Nonsentinel Lymph Node Metastasis in Early-Stage Breast Cancer Using MMP15. PubMed 36035312
- Cell Death Dis, 2022 (senior author): S100A11 activates the pentose phosphate pathway to induce malignant biological behaviour of pancreatic ductal adenocarcinoma. PubMed 35752610
- Asia Pac J Clin Oncol, 2022 (senior author): Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. PubMed 34196110
- Bioengineered, 2021 (senior author): MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. PubMed 34978519
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion